Cyclin E, an activator of cyclin-dependent kinase 2 (Cdk2) is a positive activator of the G1-S phase transition in proliferating mammalian cells and therefore serves an important function during development and in replenishment of tissues. However, cyclin E is frequently overexpressed and deregulated in human malignancies, indicating that excessive or mistimed cyclin E-Cdk2 activation can promote oncogenesis. Yet little is known about the normal or pathological functions of cyclin E at the cellular or molecular level. This proposal seeks to investigate both functions of cyclin E through a variety of in vitro and in vivo approaches.
The first aim of the proposal focuses on the roles of cyclin E in promoting entry of cells into S phase. Standard molecular and cell biological approaches will be employed. We have also embarked on a proteomic strategy to identify new proteins relevant to the S- phase promoting function of cyclin E.
The second aim utilizes cell and molecular biological approaches to elucidate the mechanism(s) whereby cyclin E deregulation causes DNA damage and genomic instability, the most likely link to oncogenesis. In the third aim, cyclin E transgenic mouse carcinogenesis models are used to test the hypothesis of cyclin E- mediated genomic instability in vivo. This is critical, as most prior work has been carried out in cell culture models, which have only a limited relevance to human cancer. Finally, we are investigating the mechanism of cyclin E turnover, since cyclin E becomes deregulated when this process fails. Interestingly, the pathway that targets cyclin E for ubiquitin-mediated proteolysis also targets several other oncoproteins, underscoring its importance for oncogenesis. It is hoped that insights gained from understanding these fundamental mechanisms of oncogenesis will lead to new approaches to cancer prevention and therapy.
Cancer is a disease with tremendous health implications for the US and world. Yet, only limited progress has been made in curing most types of cancer. In part, this is because many mechanistic questions concerning the basic biology of cancer remain unanswered. This proposal seeks to address some of these unanswered questions.
|del Rincón, S V; Widschwendter, M; Sun, D et al. (2015) Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints. Oncogene 34:1961-7|
|Bhaskaran, Nimesh; van Drogen, Frank; Ng, Hwee-Fang et al. (2013) Fbw7? and Fbw7? collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation. Mol Cell Biol 33:85-97|
|Chuang, Li-Chiou; Teixeira, Leonardo K; Wohlschlegel, James A et al. (2009) Phosphorylation of Mcm2 by Cdc7 promotes pre-replication complex assembly during cell-cycle re-entry. Mol Cell 35:206-16|
|Best, D Hunter; Coleman, William B (2007) Treatment with 2-AAF blocks the small hepatocyte-like progenitor cell response in retrorsine-exposed rats. J Hepatol 46:1055-63|
|Best, D Hunter; Coleman, William B (2007) Bile duct destruction by 4,4'-diaminodiphenylmethane does not block the small hepatocyte-like progenitor cell response in retrorsine-exposed rats. Hepatology 46:1611-9|
|Rivenbark, Ashley G; Coleman, William B (2007) Dissecting the molecular mechanisms of cancer through bioinformatics-based experimental approaches. J Cell Biochem 101:1074-86|
|Coleman, William B; Rivenbark, Ashley G (2006) Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease. J Mol Diagn 8:152-6|
|Spruck, Charles; Sun, Dahui; Fiegl, Heidi et al. (2006) Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66:7355-60|
|Rivenbark, Ashley G; Jones, Wendell D; Risher, J Devon et al. (2006) DNA methylation-dependent epigenetic regulation of gene expression in MCF-7 breast cancer cells. Epigenetics 1:32-44|
|Smith, A P L; Henze, M; Lee, J A et al. (2006) Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 25:7245-59|
Showing the most recent 10 out of 21 publications